Kedem Pharmaceuticals initiates development of sublingual cancer drug

Published: 16-Jan-2012
Drug Delivery Pharmaceutical

Gleevec is for the treatment of several blood related cancers


Kedem Pharmaceuticals, a developer of specialist pharmaceuticals with a focus on sublingual drug delivery systems, has started to develop Gleevec (imatinib), a drug for the treatment of several blood related cancers in children and adults.

In children the drug has demonstrated a powerful action against Chronic Myeloid Leukemia. The drug is administered orally and in children there is a significant issue in getting the drug swallowed, due to size of the pill and bad taste.

The firm says its sublingual formulation with taste masking features makes the drug acceptable and pleasant in taste for the children with chronic dosage requirements.

Kedem Pharmaceuticals has several other drugs under development for fast and convenient delivery. These include drugs for osteoporosis, sleeping disorders, painkillers, migraine, anti-allergy medications, cardiovascular diseases, lung medications, and addiction replacement therapies.

  • Companies:
  • Kedem Pharmaceuticals
See more

You may also like

Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

Read more
As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma

Trending Articles

  1. Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
  2. Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
  3. CDMO Adragos Pharma acquires aseptic fill-finish manufacturing expert, Baccinex Baccinex has significant knowledge in sterile fill-finish processes for both lyophilised and liquid vials
  4. Five critical design elements for Pelton wheel turbine flowmeters Titan Enterprises outlines the factors for cost-effective and reliable low-flow measurement
  5. Hovione nearly doubles pharmaceutical spray drying capabilities at Cork, Ireland facility The CDMO's multi-million investment will allow it to significantly increase its spray drying capacity, which is necessary for inhaled and oral therapeutics

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

You may also like

Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Manufacturing

Five critical design elements for Pelton wheel turbine flowmeters

Titan Enterprises outlines the factors for cost-effective and reliable low-flow measurement
Manufacturing

Hovione nearly doubles pharmaceutical spray drying capabilities at Cork, Ireland facility

The CDMO's multi-million investment will allow it to significantly increase its spray drying capacity, which is necessary for inhaled and oral therapeutics
Manufacturing

CDMO Adragos Pharma acquires aseptic fill-finish manufacturing expert, Baccinex

Baccinex has significant knowledge in sterile fill-finish processes for both lyophilised and liquid vials
Regulatory

Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China

The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
Manufacturing

Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company

The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
Packaging

Dual-chamber packaging systems as a simplification factor in the supply chain

Dual-chamber packaging solutions could represent a new frontier also to package parenteral drugs, simplifying the supply chain through reconstitution, potentially making logistics more flexible and efficient, says Cecilia Bassi, Product Manager at Bormioli Pharma
Subscribe now